Wealth Enhancement Advisory Services
INMB icon

Wealth Enhancement Advisory Services’s INmune Bio INMB Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-20,449
Closed -$39.7K – 4330
2026
Q2 		$39.7K Buy
+20,449
New +$28.3K ﹤0.01% 3952

Other funds holding INMB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Westside Investment Management
Westside Investment Management Santa Monica, California $785M AUM 29.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return
Focus Partners Advisor Solutions
Focus Partners Advisor Solutions Saint Louis, Missouri $12.4B AUM 18.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Wealth Enhancement Advisory Services's INMB Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of INmune Bio (INMB) in Q3 2026, closing a stake of 20,449 shares — an estimated $39.7K sold.

Wealth Enhancement Advisory Services first reported a position in INMB in Q2 2026 and held it in 1 quarter. The position peaked at $39.7K in Q2 2026. 26 funds tracked by Wall St. Rank hold INMB as of Q3 2026.

  • Wealth Enhancement Advisory Services reported no remaining INmune Bio position as of Q3 2026 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 20,449 INmune Bio shares in Q3 2026, an estimated $39.7K.
  • Wealth Enhancement Advisory Services first reported a position in INmune Bio in Q2 2026 and held it in 1 quarter.
  • Wealth Enhancement Advisory Services's INmune Bio position peaked at $39.7K in Q2 2026.
  • 26 funds tracked by Wall St. Rank held INmune Bio as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.